Immuno-Oncology Drugs Market Trends And
Growth By 2025
Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by
stimulating the immune system instead of fighting the tumors, avoiding disturbance in
functionality of healthy cells. It helps the immune system to recognize and target cancer cells.
The therapy facilitates long term response against cancer by providing long-lasting memory to
the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which
include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma,
breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies
such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy,
cancer vaccines, and other therapies. Depending on the functioning of these therapies they are
further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and
bispecific monoclonal antibodies. Commercially available immune-oncology therapies include
Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1271
Introduction of novel immune-oncology therapies with lesser side effects is driving growth of
the global immune-oncology drugs market
Improved therapeutic outcomes have led to increasing success rates against cancer, owing to in-
depth understanding of the disease pathophysiology, functioning of the tumor cells, and
effective ways to tackle with the same. Moreover, immuno-oncology therapies have lesser side
effects compared to conventional cancer therapies such as chemotherapy, radiation therapy, and
others. Immuno-oncology therapy operates through the immune system of the body and does
not harm healthy cells as opposed to conventional therapies such as targeted therapy,
chemotherapy, and radiation therapy that affect cancerous as well as healthy cells. Novel
immune therapies can restore the ability of the immune system to identify and eliminate cancer
cells, which is generally suppressed during course of cancer progression. Such immuno-oncology
based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a,
human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is
available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed